Use of 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) for the determination of ramipril in tablets and spiked human plasma

Farmaco

Volumn 56, Issue 4, 2001, Pages 291-296

  Al Majed, A A ^a   Al Zehouri, J ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

ACE; Colorimetry; Fluorimetry; NBD F; Plasma; Ramipril; Tablets

Indexed keywords

7 FLUORO 4 NITROBENZO 2 OXO 1,3 DIAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; REAGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLUORESCENCE; HUMAN; HUMAN TISSUE; NORMAL HUMAN; REACTION ANALYSIS; SPECTROFLUOROMETRY; TABLET; TECHNIQUE;

4-CHLORO-7-NITROBENZOFURAZAN; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALIBRATION; FLUORESCENT DYES; HUMANS; HYDROGEN-ION CONCENTRATION; INDICATORS AND REAGENTS; RAMIPRIL; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS;

EID: 0035305695     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(01)01070-9     Document Type: Article

References (20)

1. Martindale, The Extra Pharmacopoeia, 31st ed., The Royal Pharmaceutical Society.
2. Metzger H., Maier R., Sitter C., Stern H.O. 2-[N-(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3. 0]octane-3-carboxylic acid (HOE 489)- a new and highly effective angiotensin I converting enzyme inhibitor. Arzneim. Forsch. (Drug Res.). 34:1984;1402-1406.
3. Lenz T., Distle A., Haller H., Sabllek W.H., Wilp C., Tensey M.J., Eckert H.G., Metzger H., Irmishc R., Philipp T. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension. Arzneim. Forsch. (Drug Res.). 36:1986;1693-1696.
4. Manheim P.J.O., Ball S.G., Morton J.J., Murray G.D., Leckie B.J., Fraser R., Robertson J.I.S. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man. Br. J. Clin. Pharmacol. 20:1985;27-35.
5. Imai K., Ueda E., Toyoóka T. High-performance liquid chromatography with photochemical fluorimetric detection of tryptophan based on 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole. Anal. Chim. Acta. 206:1988;7-14.
6. Bonazzi D., Gotti R., Andrisano V., Cavrini V. Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC). J. Pharm. Biomed. Anal. 16:1997;431-438.
7. Schmidt D., Keller A., Fresenius Z. Sensitive determination of the acetyl choline estrase-inhibitor HOE 498 and its metabolites in human urine by capillary GC. Anal. Chem. 320:1985;731.
8. Sereda M.K., Hardman T., Dilloway M.R., Lant A.F. Development of a method for detection of angiotensin-converting enzyme [peptidyl-dipeptidase A] inhibitors using electron-capture gas chromatography detection. Anal. Proc. 30:1993;371-372.
9. Aboul-Enein H.Y., Baker S.A. High performance liquid chromatographic identification of ramipril and its precursor enantiomers using a chiralpak OT (+)-column. Drug Dev. Ind. Pharm. 18:1992;1013-1022.
10. Aboul-Enein H.Y., Thiffault C. Determination of ramipril and its precursors by reversed-phase high performance liquid chromatography. Anal. Lett. 24:1991;2217-2224.
11. Ito M., Kuriki T., Goto J., Nambara T. Separation of ramipril optical isomers by high-performance liquid chromatography. J. Liq. Chromatogr. 13:1990;991-1000.
12. Eckert H.G., Münscher G., Oekonomopulos R., Strecker H., Vrbach H., Wissman H. Radio-immunoassay for the angiotensin-converting enzyme [dipeptidyl carboxypeptidase] inhibitor ramipril and its active metabolite. Arzneim. Forsch. (Drug Res.). 35:1985;1251-1256.
13. Abdellatef H.E., Ayad M.M., Taha A.E. Spectrophotometric and atomic absorption spectrometric determination of ramipril and perindopril through ternary complex formation with eosin and copper (II) ions. J. Pharm. Biomed. Anal. 18:1999;1021-1027.
14. Al-Majed A.A., Belal F., Abadi A., Al-Obaid A.M. The voltammetric study and determination of ramipril in dosage forms and biological fluids. Farmaco. 55:2000;233-238.
15. Imai K., Uzu S., Toyoóka T. Availability of fluorogenic reagents having a benzofurazan structure in the biosciences. Anal. Chim. Acta. 290:1994;3-20.
16. Imai K., Uzu S., Toyoóka T. Fluorogenic reagents having benzofurazan structure in liquid chromatography. J. Pharm. Biomed. Anal. 7:1989;1395-1403.
17. Christian G.D., Reilly J.E.O. Instrumental Analysis. second ed. 1986;186 Prentice Hall, Englewood Cliffs, NJ.
18. Witte P.U., Irmisch R., Hajdu P., Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. Eur. J. Clin. Pharmacal. 27:1984;577-581.
19. Donaubauer H.H., Mayer D. Acute subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril. Arzneim. Forsch. (Drug Res.). 38:1998;14-20.
20. Aboul-Enein H.Y., Bunacio A.A., Bala C., Fleischin S. Enalapril and ramipril selective membranes. Anal. Lett. 30:1997;1999-2008.